In Vitro Antibody Assays using Therapeutic Antibodies
Selection of the best cellular model for your study among:
- Various hematological cancer cell lines (AML, DLBCL, MM, MCL…)
- Unique proprietary panel of multiple myeloma cell lines (n=25)
- Primary samples from patients with hematological malignancies (Multiple Myeloma, Non-Hodgkin Lymphoma, Acute and Chronic Leukemia…)
- Access to general information, genomic and clinical data from samples (age, gender, subtypes, gene expression profile, mutations, FISH, epigenetic data, treatment and response…)
- Access to longitudinal samples at diagnosis, end of treatment and relapses.
In Vitro assays to investigate the direct and indirect cell-mediated cytotoxicity
- Cell viability assays, Drug combinations
- ADCC assays using PBMC or NK cells from patients or healthy donor
- Immunophenotyping and Monitoring of B, T and NK cells subtypes using multiparameter flow cytometry
- Hematological cancer cell lines
- Primary cells from patients with hematologic malignancies
- Multiparameter flow cytometry (13 colors)
- Cell viability assays
- Drug combinaisons using conventional of target treatments
- In vitro assessment of antibodies autologous cytotoxicity
- In vitro assessment of antibodies heterologous cytotoxicity
- Customized services on request
- A Final Report
- Raw and Treated data
Immunogenomic Analysis
We propose a creating comprehensive portrait of the tumor cells and their microenvironment using RNA and DNA sequencing data from patients with various hematological cancers. Also, we propose a development of a cloud-based analytic platform to analyse and visualize your immunogenomic data.
Transcriptomic characterization of immune activities within tumor micro-environment
- Tumor Immunogenicity
- Tumor inflammatory signature
- Anti-tumor immune activities
- Inhibitory Immune Signaling
- Immune infiltration (deconvolution of heterogeneous samples)
Identification of relevant mutations and Tumor Mutational Burden (TMB)
- Mutated oncogenic pathways
- Mutated genes and durg interaction
- Estimation of Tumor Mutational load
TCR profiling using NGS
- Identification of T cell clones by analyzing CDR3 region
- Visualization of the number of clones and their proportion
- Calculation of Shannon entropy (Clonal diversity)
- Access to large cohorts of RNAseq data from primary samples already sequenced (MM, LLC, DLBCLs, DLBCLs, FL, MCL, ZML)
- Access to WESseq data of primary samples already sequenced (MM, LLC, DLBCLs, DLBCLs, FL, MCL, ZML)
- Access to DNA and RNA of a large panel of primary samples (longitudinal samples, MM, LLC, DLBCLs, DLBCLs, FL, MCL, ZML, AML, ALL…)
- Possibilities to perform sequencing of your samples or after treatment studies
- RNA/DNA extraction
- RNAseq, WES, target sequencing
- Immune composition
- Immune activities
- TCR profiling
- HLA typing
- Biomarkers identification
- Customized services
- A final report
- Raw and aligned data
- A cloud-based analytic platform to analyze and visualize the immunogenomic data
